vikingtherapeutics.com (VKTX) - Company Net Income

Official company branding of Viking Therapeutics, Inc. (VKTX)

Viking Therapeutics (VKTX) maintains financial stability based on the preparation of production capacities and successful tests of obesity treatments. The company's net income dynamics clearly demonstrate current cash flows, where -0.63 represents the current level of this metric. Growth prospects are driven by the success of the VK2735 drug and potential mergers with industry behemoths. The business is protected by unique patents amidst fierce global competition.

VKTX Viking Pharma Company Net Income (07/04/2022 - 11/01/2026)

Analytical breakdowns and data insights for company Viking Therapeutics, Inc. (VKTX)

- stock value and consensus price forecast:
Market Price Viking Therapeutics Corp|VKTX - Consensus Target
- market capitalization indicators:
Market Value Viking Therapeutics Corp|VKTX - Enterprise Value
- book capitalization indicators:
Net Assets per Share Viking Therapeutics|VKTX - Company Book Value|Market Capitalization to Book Value Ratio vikingtherapeutics.com|VKTX - Company Total Assets
- debt burden and liquidity indicators:
Total Debt to Capital Coefficient Viking Therapeutics|VKTX - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Viking Therapeutics Inc|VKTX - Company Aggregate Debts|Debt to Net Assets Viking Therapeutics Corp|VKTX - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Viking Therapeutics|Intermediate Liquidity Ratio vikingtherapeutics.com
- earnings and multiples data:
VKTX - Net Profit
Fundamental valuation:VKTX (Viking Therapeutics Corp)
Mass-produced product of Viking Therapeutics Corp

Active collaborations between Viking Therapeutics (VKTX) and research centers developing drugs for metabolic pathologies directly impact operating expenses and the bottom line. By analyzing the difference between total revenue and all costs, investors use the company's profit margins to determine the real momentum of business development, separating market noise from fundamental dynamics and assessing the risks of price stagnation.

Key competitors

Company Net Income Biogen Idec (BIIB)|Net Income NBIX|Company Net Income RGC|Net Profit AXSM|Net Financial Result ACADIA Pharma|Company Net Income Xenon Pharmaceuticals Inc XENE|Net Profit Supernus Corp SUPN|Catalyst Pharmaceuticals - Net Profit|Net Financial Result denalitherapeutics.com DNLI|Harmony Biosciences Holdings, Inc. (HRMY) - Company Net Income|Company Profit BHVN|AMLX (Amylyx) - Net Profit|TRVI - Annual Net Income|Net Income PRAX (Praxis Precision Medicines)|AVXL (anavex.com) - Final Profit|CeriBell - Net Income|Profit After Payment of Taxes PRTA (Prothena Corp)|Alector Therapeutics - Net Profit|Final Profit ANNX (Annexon Biosciences Inc.)|OMER: Net Profit|Company Net Income neurogene.com (NGNE)|Company Net Income AC Immune SA|VYGR: Final Profit|Net Profit NMRA|Net Profit Scilex Holding Company, Inc. (SCLX)|Company Net Income Tevogen Bio Holdings TVGN|ACOG (Alpha Cognition Inc) - Profit After Tax|Cognition Therapeutics - Net Profit|Company Net Income Inhibikase Therapeutics Inc|SAVA (Cassava) - Net Income|Assertio (ASRT) - Net Profit|Net Income COYA|VTGN (VistaGen Therapeutics Inc) - Profit After Payment of Taxes|Net Profit OVID|Net Financial Result Acumen Pharmaceuticals Inc.|Net Profit CRVO (CervoMed Inc)|ATHE - Net Income|CLNN - Company Net Income|Net Financial Result PepGen Inc. PEPG|JUNS (Jupiter Neurosciences Inc) - Net Income|RLMD (Relmada Therapeutics Inc) - Company Net Income|Company Net Income Annovis Bio Corp|Net Profit Grace Tx|Net Income AIFF (Firefly Neuroscience, Inc)|Profit After Payment of Taxes KLTO|NeuroSense Therapeutics Ltd. - Net Income|RVPH: Company Profit|MTVA - Company Net Income|NRXS (NeurAxis Inc) - Company Profit|HSDT: Net Profit|Company Net Income Passage Bio (PASG)|Net Income NEUP|Net Profit Minerva Neurosciences Inc|Company Net Income Athira (ATHA)|ADXN (Addex) - Final Profit|Company Net Income Alzamend Neuro ALZN|Cyclerion Therapeutics Inc. (CYCN) - Company Net Income|PTIX: Net Income|KTTA: Company Net Income|CRGT: Net Profit|ATXI - Net Financial Result|Company Net Income Brainstorm Cell|Net Profit caratherapeutics.com|Net Profit CHRO|Net Financial Result eliemtx.com|Company Net Income Intra-Cellular Therapies, Inc. ITCI|LBPH: Company Profit|Marinus Pharmaceuticals - Net Profit|Annual Net Income nkgenbiotech.com (NKGN)|NRBO (NeuroBo Pharmaceuticals, Inc.) - Net Income|Sage Therapeutics Inc. - Final Profit|Net Income SNPX|TRVN (Trevena Inc) - Profit After Payment of Taxes|Net Profit VIGL|WENA (Anew Medical Inc.) - Final Profit|Net Profit CERE (Cerevel Therapeutics, Inc.)